Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease

References

• Stopschinski BE, Diamond MI. The prion model for progression and diversity of neurodegenerative diseases. Lancet Neurol 2017;16:323–32.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association (USA). World Alzheimer Report. 2015. Available from: http://news.medlive.cn/uploadfile/20150902/14411602338388.pdf
   Google Scholar
• Goedert M, Spillantini MG. A century of Alzheimer’s disease. Science 2006;314:777–81.
   PubMed Web of Science ®Google Scholar
• Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs 2011;71:2031–65.
   PubMed Web of Science ®Google Scholar
• Terry AV, Callahan PM, Hall B, et al. Alzheimer’s disease and age-related memory decline (preclinical). Pharmacol Biochem Behav 2011;99:190–210.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Caporaso R, et al. Multitarget strategies in Alzheimer’s disease: benefits and challenges on the road to therapeutics. Future Med Chem 2016;8:697–711.
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 2014;76:27–50.
   PubMed Web of Science ®Google Scholar
• Azevedo MF, Faucz FR, Bimpaki E, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195–233.
   PubMed Web of Science ®Google Scholar
• Maurice DH, Ke HM, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014;13:290–314.
   PubMed Web of Science ®Google Scholar
• Ricciarelli R, Fedele E. Phosphodiesterase 4D: an enzyme to remember. Br J Pharmacol 2015;172:4785–9.
   PubMed Web of Science ®Google Scholar
• Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, et al. Phosphodiesterases as therapeutic targets for Alzheimer’s disease. ACS Chem Neurosci 2012;3:832–44.
   PubMed Web of Science ®Google Scholar
• Reyes-Irisarri E, Ittersum MMV, Mengod G, et al. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer’s disease human brains. Eur J Neurosci 2007;25:3332–8.
   PubMed Web of Science ®Google Scholar
• van der Staay FJ, Rutten K, Barfacker L, et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008;55:908–18.
   PubMed Web of Science ®Google Scholar
• Kroker KS, Mathis C, Marti A, et al. PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition. Neurobiol Aging 2014;35:2072–8.
   PubMed Web of Science ®Google Scholar
• Kroker KS, Rast G, Giovannini R, et al. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012;62:1964–74.
   PubMed Web of Science ®Google Scholar
• Li J, Liu CN, Wei N, et al. Protective effects of BAY 73-6691, a selective inhibitor of phosphodiesterase 9, on amyloid-beta peptides-induced oxidative stress in in vivo and in vitro models of Alzheimer’s disease. Brain Res 2016;1642:327–35.
   PubMed Web of Science ®Google Scholar
• Hutson PH, Finger EN, Magliaro BC, et al. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology 2011;61:665–76.
   PubMed Web of Science ®Google Scholar
• Verhoest PR, Fonseca KR, Hou XJ, et al. Design and discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J Med Chem 2012;55:9045–54.
   PubMed Web of Science ®Google Scholar
• Schwam EM, Nicholas T, Chew R, et al. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer’s disease. Curr Alzheimer Res 2014;11:413–21.
   PubMed Web of Science ®Google Scholar
• Su T, Zhang TH, Xie SS, et al. Discovery of novel PDE9 inhibitors capable of inhibiting A beta aggregation as potential candidates for the treatment of Alzheimer’s disease. Sci Rep 2016;6:21826.
   PubMed Web of Science ®Google Scholar
• Yu YF, Huang YD, Zhang C, et al. Discovery of novel pyrazolopyrimidinone derivatives as PDE9A inhibitors capable of inhibiting BuChE for treatment of Alzheimer’s disease. ACS Chem Neurosci 2017;8:2522–34.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Milelli A, et al. Oxidative stress in Alzheimer’s disease: are we connecting the dots? J Med Chem 2014;57:2821–31.
   PubMed Web of Science ®Google Scholar
• Mecocci P, Polidori MC. Antioxidant clinical trials in mild cognitive impairment and Alzheimer’s disease. Biochim Biophys Acta 2012;1822:631–8.
   PubMed Web of Science ®Google Scholar
• Zhang HY, Yang DP, Tang GY. Multipotent antioxidants: from screening to design. Drug Discov Today 2006;11:749–54.
   PubMed Web of Science ®Google Scholar
• Deshmukh R, Sharma V, Mehan S, et al. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine–a PDE1 inhibitor. Eur J Pharmacol 2009;62:49–56.
   Web of Science ®Google Scholar
• Li Z, Lu X, Feng LJ, et al. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Mol Biosyst 2015;11:115–25.
   PubMed Web of Science ®Google Scholar
• Claffey MM, Helal CJ, Verhoest PR, et al. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active Phosphodiesterase 9A inhibitors. J Med Chem 2012;55:9055–68.
   PubMed Web of Science ®Google Scholar
• Rosini M, Simoni E, Bartolini M, et al. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer’s disease. Eur J Med Chem 2011;46:5435–42.
   PubMed Web of Science ®Google Scholar
• Wang H, Yan Z, Yang S, et al. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry 2008;47:12760–8.
   PubMed Web of Science ®Google Scholar
• Reed TM, Browning JE, Blough RI, et al. Genomic structure and chromosome location of the murine PDE1B phosphodiesterase gene. Mamm Genome 1998;9:571–6.
   PubMed Web of Science ®Google Scholar
• Ou BX, Hampsch-Woodill M, Prior RL. Development and validation of an improved oxygen radical absorbance capacity assay using fluorescein as the fluorescent probe. J Agr Food Chem 2001;49:4619–26.
   PubMed Web of Science ®Google Scholar
• Davalos A, Gomez-Cordoves C, Bartolome B. Extending applicability of the oxygen radical absorbance capacity (ORAC-fluorescein) assay. J Agric Food Chem 2004;52:48–54.
   PubMed Web of Science ®Google Scholar
• Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986;89:271–7.
   PubMed Web of Science ®Google Scholar
• Meng F, Hou J, Shao YX, et al. Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design. J Med Chem 2012;55:8549–58.
   PubMed Web of Science ®Google Scholar
• Jain AN. Surflex: fully automatic flexible molecular docking using a molecular similarity-based search engine. J Med Chem 2003;46:499–511.
   PubMed Web of Science ®Google Scholar
• Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov 2000;18:113–35.
   Google Scholar
• Hou TJ, Wang JM, Li YY, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model 2011;51:69–82.
   PubMed Web of Science ®Google Scholar
• Xu L, Sun HY, Li YY, et al. Assessing the performance of MM/PBSA and MM/GBSA methods. 3. The impact of force fields and ligand charge models. J Phys Chem B 2013;117:8408–21.
   PubMed Web of Science ®Google Scholar
• Case DA, Betz RM, Cerutti DS, et al. Amber 2016. San Francisco, CA: University of California; 2016.
   Google Scholar
• Sang ZP, Pan WL, Wang KR, et al. Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Eur J Med Chem 2017;130:379–92.
   PubMed Web of Science ®Google Scholar
• Chen ZW, Digiacomo M, Tu YL, et al. Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer’s disease. Eur J Med Chem 2017;125:784–92.
   PubMed Web of Science ®Google Scholar
• Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719–40.
   PubMed Web of Science ®Google Scholar
• Wunder F, Tersteegen A, Rebmann A, et al. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 2005;68:1775–81.
   PubMed Web of Science ®Google Scholar